Cambridge Healthtech Institute Presents the 2nd Annual Oncology Clinical Trials Conference

PRLog (Press Release) - Oct. 31, 2011 - Attendees of this meeting will hear recent breakthroughs in the molecular biology of cancer that have led to an unprecedented number of new targets in oncology drug development. Many of these are already advancing to the clinical stages, making oncology clinical trials the most prevalent across therapeutic areas. The success of an oncology trial depends on many factors, the most important being the quality of pre-clinical data that provides a testable hypothesis. Biostatistical, scientific, organizational, regulatory, ethical and economic ingredients are equally important for advancing clinical development of a drug.

Keynote addresses include:

* Cancer Clinical Trials in the Era of Personalized Medicine: a Sponsor's Perspective by
 Hal Barron, M.D., Executive Vice President, CMO, Global Product Development, Roche
 Holding AG

* Methodologic Issues in Clinical Trials in the Era of Personalized Therapy by Margaret
  A. Tempero, M.D., Doris and Donald Fisher Distinguished Professorship, Clinical
 Cancer Research; Professor, Medicine, Division of Hematology and Oncology; Director,
 Research Programs; Deputy Director, UCSF Helen Diller Family Comprehensive
 Cancer Center

* Cancer Clinical Trials in the Era of Personalized Medicine: An Investigator's Perspective
  Steven Piantadosi, M.D., Ph.D., Chair & Director, Phase One Foundation, Samuel
  Oschin Comprehensive Cancer Institute

As part of the Molecular Med TRI-CON 2012, attendees have access to 2 partnering forums, 5 symposia, 18 short courses, and 12 core programs. The event attracts than 3,000 attendees and provides attendees an opportunity to interact with each other in the shared exhibit/poster hall, plenary keynotes and social functions.

Early registration discounts are available until November 18. For complete event details visit: http://www.triconference.com/cct.

To inquire about sponsoring and/or exhibiting, contact Jon Stroup, 781-972-5483, jstroup@healthtech.com.

Writers and editors are encouraged to attend. To request a press pass, contact Tracey Fielding at tfielding@healthtech.com.

About Cambridge Healthtech Institute (www.chicorporate.com)

Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI’s portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Barnett International, Cambridge Marketing Consultants, Cambridge Meeting Planners and Cambridge Healthtech’s Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.

Founded in 1992, Cambridge Healthtech Institute strives to develop quality information sources that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business.

Contact:
James Prudhomme
Cambridge Healthtech Institute
781-972-5400
jprudhomme@healthtech.com